Asset profile
roflumilast · Zoryve
Small molecule
Evidence outlook
Approved: Atopic Dermatitis (label: mild to moderate atopic dermatitis in adults and pediatric patients 6 years and older), Psoriasis (label: plaque psoriasis, including intertriginous areas), Plaque Psoriasis, Seborrheic Dermatitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
124 competitors in this universe: 6 direct rivals (same mechanism and indication), 3 same-class, 115 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Roflumilast (Zoryve): this drug | Approved | Small molecule | PDE4 | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Hemay005 | Phase 3 | Small molecule | PDE4 | ||
| HPP737 | Phase 3 | Small molecule | PDE4 | ||
| PF-07038124 | Phase 2 | Small molecule | PDE4 | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 | ||
| ALTO-101 | Phase 2 | Small molecule | PDE4 | ||
| PALI-2108 | Phase 2 | Small molecule | PDE4 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A |
…and 109 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (7)
February 2027 (1)
What to watch
March 2027 (1)
What to watch
June 2027 (2)
July 2027 (1)
2028 (2)
2030 (1)
June 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.